TY - JOUR
T1 - Guidelines of care for the management of actinic keratosis
AU - Eisen, Daniel B.
AU - Asgari, Maryam M.
AU - Bennett, Daniel D.
AU - Connolly, Suzanne M.
AU - Dellavalle, Robert P.
AU - Freeman, Esther E.
AU - Goldenberg, Gary
AU - Leffell, David J.
AU - Peschin, Sue
AU - Sligh, James E.
AU - Wu, Peggy A.
AU - Frazer-Green, Lindsy
AU - Malik, Sameer
AU - Schlesinger, Todd E.
N1 - Funding Information:
Funding sources: This study was funded in total by internal funds from the American Academy of Dermatology .
Funding Information:
Funding sources: This study was funded in total by internal funds from the American Academy of Dermatology.Maryam M. Asgari, MD, MPH, serves as an investigator for Pfizer, Inc. receiving grants and/or research funding.Robert P. Dellavalle, MD, PhD, MSPH, serves as a principal investigator for Pfizer, Inc and the U.S. Department of Veterans Affairs receiving grants and/or research funding; as an editorial board member for the Cochrane Collaboration, Journal of Investigative Dermatology, and the Journal of the American Academy of Dermatology receiving other financial benefits; as an independent contractor for UpToDate, Inc receiving patent royalties and/or compensation for intellectual property rights; as a consultant for Altus Labs and ParaPRO LLC receiving fees and/or stock.Gary Goldenberg?, MD, serves as an investigator for Leo Pharma Inc, Pharmaderm, Stiefel (a GSK company), and Valeant Pharmaceuticals North America LLC receiving grants and/or research findings; as a consultant for Allergan, Inc, Alma Lasers, Anacor Pharmaceuticals, Inc, Bayer Pharmaceuticals, Celgene Corporation, Eclipse Medical, Eli Lilly and Company, Genentech, Inc, Janssen Pharmaceuticals, Inc, Leo Pharma US, MelaSciences, Novartis Pharmaceuticals Corp, Ranbaxy Laboratories Limited, Stiefel (a GSK company), Taro Pharm, Teva Pharmaceuticals USA, Valeant Pharmaceuticals North America LLC, and Xoft receiving honoraria and/or fees; as a speaker for AbbVie, Bayer Pharmaceuticals, Castle Biosciences, Celgene Corporation, Eli Lilly and Company, Galderma USA, LEO Pharma US, Novartis Pharmaceuticals Corp, Pharmaderm, and Valeant Pharmaceuticals North America LLC receiving honoraria; as an advisory board member for Dermira and Pharmaderm receiving honoraria.Todd E. Schlesinger, MD,? serves as an investigator for AbbVie, Aclaris Therapeutics, Inc, Arcutis Premier Research, Arcutis Biotherapeutics, Akros, Allergan, Astellas Pharma US, AOBiome Therapeutics, Bioderma, Biofrontera, BioPharmx, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle BioScience, Celgene, Centocor Ortho Biotech, Inc, ChemoCentryx, Coherus Biosciences, Corrona, Inc, Demira, Dermavant Sciences, DT Pharmacy & DT Collagen, Eli Lilly and Company, Galderma USA, Genentech, Janssen Pharmaceuticals, Kinex, Kiniksa Pharmaceuticals, Ltd., LEO Pharmaceuticals, Merz Aesthetics, Novartis, Pfizer, Regeneron, Regeneron Pharmaceuticals, Sanofi, Sebacia, Inc, Sienna Biopharmaceuticals, SiSaf Ltd., Tetra Derm Group, LLC., and Trevi receiving grants and/or research funding; as a consultant for AbbVie, Aclaris Therapeutics, Inc, Allergan, Inc, Almirall, BioFrontera, Bristol-Meyers Squibb, Castle Biosciences, Eli Lilly and Company, Evolus, Foundation for Research and Education in Dermatology, EPI Health, Galderma USA, LEO Pharmaceuticals, Lilly, MED Learning Group CME Program, Merz Aesthetics, MJH Associates, Nextphase, Novartis, Ortho Dermatologics, Pfizer, Inc, Prolacta Bioscience, Regeneron, SiSaf Ltd, Sun Pharma, Suneva Medical, UCB, Unilever, and Verrica receiving honoraria and/or fees; as a speaker for Aclaris, Almirall, Demira, DUSA, EPI Health, Regeneron, Sanofi Genzyme, Sun Pharma, Suneva Medical, Inc, and Sun Pharmaceutical Industries Ltd receiving honoraria; as an advisory board member for Allergan, Almirall, Amgen, Bioderma, Biofrontera AG, Celgene, Greenway Therapeutix (no compensation received), Remedly, Inc, and Suneva Medical, Inc receiving honoraria and/or stock; as an independent contractor for SiSaf Ltd receiving grants and/or research funding.
Funding Information:
Todd E. Schlesinger, MD,∗ serves as an investigator for AbbVie , Aclaris Therapeutics, Inc , Arcutis Premier Research , Arcutis Biotherapeutics , Akros , Allergan , Astellas Pharma US , AOBiome Therapeutics , Bioderma , Biofrontera , BioPharmx , Boehringer Ingelheim , Bristol-Myers Squibb , Cara Therapeutics , Castle BioScience , Celgene , Centocor Ortho Biotech, Inc , ChemoCentryx , Coherus Biosciences , Corrona, Inc , Demira , Dermavant Sciences , DT Pharmacy & DT Collagen , Eli Lilly and Company , Galderma USA , Genentech , Janssen Pharmaceuticals , Kinex , Kiniksa Pharmaceuticals, Ltd. , LEO Pharmaceuticals , Merz Aesthetics , Novartis , Pfizer , Regeneron , Regeneron Pharmaceuticals , Sanofi , Sebacia, Inc , Sienna Biopharmaceuticals , SiSaf Ltd. , Tetra Derm Group, LLC. , and Trevi receiving grants and/or research funding; as a consultant for AbbVie, Aclaris Therapeutics, Inc, Allergan, Inc, Almirall, BioFrontera, Bristol-Meyers Squibb, Castle Biosciences, Eli Lilly and Company, Evolus, Foundation for Research and Education in Dermatology, EPI Health, Galderma USA, LEO Pharmaceuticals, Lilly, MED Learning Group CME Program, Merz Aesthetics, MJH Associates, Nextphase, Novartis, Ortho Dermatologics, Pfizer, Inc, Prolacta Bioscience, Regeneron, SiSaf Ltd, Sun Pharma, Suneva Medical, UCB, Unilever, and Verrica receiving honoraria and/or fees; as a speaker for Aclaris, Almirall, Demira, DUSA, EPI Health, Regeneron, Sanofi Genzyme, Sun Pharma, Suneva Medical, Inc, and Sun Pharmaceutical Industries Ltd receiving honoraria; as an advisory board member for Allergan, Almirall, Amgen, Bioderma, Biofrontera AG, Celgene, Greenway Therapeutix (no compensation received), Remedly, Inc, and Suneva Medical, Inc receiving honoraria and/or stock; as an independent contractor for SiSaf Ltd receiving grants and/or research funding.
Publisher Copyright:
© 2021 American Academy of Dermatology, Inc.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Actinic keratoses (AK) are rough scaly patches that arise on chronically ultraviolet-exposed skin and can progress to keratinocyte carcinoma. Objective: This analysis examined the literature related to the management of AK to provide evidence-based recommendations for treatment. Grading, histologic classification, natural history, risk of progression, and dermatologic surveillance of AKs are also discussed. Methods: A multidisciplinary Work Group conducted a systematic review to address 5 clinical questions on the management of AKs and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading clinical recommendations. Graded recommendations were voted on to achieve consensus. Results: Analysis of the evidence resulted in 18 recommendations. Limitations: This analysis is based on the best available evidence at the time it was conducted. The pragmatic decision to limit the literature review to English language randomized trials may have excluded data published in other languages or limited identification of relevant long-term follow-up data. Conclusions: Strong recommendations are made for using ultraviolet protection, topical imiquimod, topical 5-fluorouracil, and cryosurgery. Conditional recommendations are made for the use of photodynamic therapy and diclofenac for the treatment of AK, both individually and as part of combination therapy regimens.
AB - Background: Actinic keratoses (AK) are rough scaly patches that arise on chronically ultraviolet-exposed skin and can progress to keratinocyte carcinoma. Objective: This analysis examined the literature related to the management of AK to provide evidence-based recommendations for treatment. Grading, histologic classification, natural history, risk of progression, and dermatologic surveillance of AKs are also discussed. Methods: A multidisciplinary Work Group conducted a systematic review to address 5 clinical questions on the management of AKs and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of the evidence and formulating and grading clinical recommendations. Graded recommendations were voted on to achieve consensus. Results: Analysis of the evidence resulted in 18 recommendations. Limitations: This analysis is based on the best available evidence at the time it was conducted. The pragmatic decision to limit the literature review to English language randomized trials may have excluded data published in other languages or limited identification of relevant long-term follow-up data. Conclusions: Strong recommendations are made for using ultraviolet protection, topical imiquimod, topical 5-fluorouracil, and cryosurgery. Conditional recommendations are made for the use of photodynamic therapy and diclofenac for the treatment of AK, both individually and as part of combination therapy regimens.
KW - actinic keratosis
KW - actinic keratosis guidelines
KW - clinical guidelines for actinic keratosis
KW - cryosurgery
KW - dermatology
KW - photodynamic therapy
KW - topical agents
UR - http://www.scopus.com/inward/record.url?scp=85103710455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103710455&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2021.02.082
DO - 10.1016/j.jaad.2021.02.082
M3 - Article
C2 - 33820677
AN - SCOPUS:85103710455
SN - 0190-9622
VL - 85
SP - e209-e233
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -